Neil Lerner, Chief Accounting Officer of Compass Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing an open-market purchase of 10,000 shares of common stock on November 17, 2026.
Key Highlights
- Transaction: Neil Lerner acquired 10,000 shares of Compass Therapeutics common stock on November 17, 2026, at a price of $0.59 per share.
- Transaction code: The filing reports a "P" (open-market purchase) under Transaction Code.
- Resulting ownership: Following the purchase, Lerner beneficially owns 430,000 shares of common stock directly.
- RSU component: Of the 430,000 shares reported, 62,500 represent unvested restricted stock units granted on January 2, 2026, each representing a contingent right to receive one share of common stock.
- RSU vesting schedule: The RSU award vests in four equal annual installments, with the first installment vesting on January 2, 2027, subject to service-based conditions.
- Reporting person role: Lerner is identified in the filing as Chief Accounting Officer of Compass Therapeutics, Inc. (NASDAQ:CMPX).
Compass Therapeutics Chief Accounting Officer Discloses November 17 Purchase
According to the Form 4 filed with the SEC on November 18, 2026, Neil Lerner, Chief Accounting Officer of Compass Therapeutics, Inc. (NASDAQ:CMPX), purchased 10,000 shares of the company's common stock on November 17, 2026, at a price of $0.59 per share. The transaction was coded "P," indicating an open-market purchase. The filing does not indicate any connection to a Rule 10b5-1 trading plan.
Following the reported transaction, the filing states that Lerner directly and beneficially owns 430,000 shares of Compass Therapeutics common stock. The filing includes a footnote disclosing that 62,500 of those shares represent unvested restricted stock units granted on January 2, 2026. According to the filing, each RSU represents "a contingent right to receive one share of common stock," and the award "is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."
No derivative securities transactions were reported in Table II of the filing. The form was signed by Neil Lerner and dated November 18, 2026.
What Was Disclosed
Compass Therapeutics Chief Accounting Officer Neil Lerner disclosed an open-market purchase of 10,000 shares of common stock at $0.59 per share on November 17, 2026, bringing his total direct beneficial ownership to 430,000 shares, which includes 62,500 unvested RSUs.




Please wait processing your request...